Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TFEB | P19484 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392535 | 0.81 | PTGDR2 (0.41) | PTGDR2NFE2L2ALDH1A1HPGDHTT | |
| SCHEMBL9903250 | 0.81 | PTGDR2 (0.41) | PTGDR2NFE2L2ALDH1A1HPGDHTT | |
| SCHEMBL4193610 | 0.78 | NFE2L2 (0.41) | PTGDR2NFE2L2ALDH1A1HPGDHTT | |
| SCHEMBL26106629 | 0.77 | ALDH1A1 (0.55) | PTGDR2NFE2L2ALDH1A1HPGDHTT | |
| SCHEMBL4585584 | 0.74 | KMT2A (0.40) | PTGDR2NFE2L2ALDH1A1HPGDHTT | |
| SCHEMBL29728552 | 0.72 | KMT2A (0.52) | ALDH1A1HPGDHTTSMN1; SMN2KDM4E | |
| SCHEMBL7029967 | 0.72 | KMT2A (0.52) | ALDH1A1HPGDHTTSMN1; SMN2KDM4E | |
| SCHEMBL25435693 | 0.71 | CDK4 (0.52) | PTGDR2NFE2L2ALDH1A1HPGDHTT | |
| SCHEMBL13516901 | 0.71 | KMT2A (0.54) | ALDH1A1HPGDSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL31522630 | 0.70 | TSHR (0.47) | ALDH1A1HPGDSMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | PCNA, MCL1, MYC | PTGDR2 922/4885NFE2L2 349/4885ALDH1A1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.